Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146790

Pw146790 View Pathway
drug action

Zinc dibutyldithiocarbamate Drug Metabolism Action Pathway

Homo sapiens

PW145462

Pw145462 View Pathway
drug action

Zinc Drug Metabolism Action Pathway

Homo sapiens

PW132215

Pw132215 View Pathway
metabolic

Zinc gluconate Drug Metabolism

Homo sapiens
Zinc gluconate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zinc gluconate passes through the liver and is then excreted from the body mainly through the kidney.

PW146318

Pw146318 View Pathway
drug action

Zinc gluconate Drug Metabolism Action Pathway

Homo sapiens

PW146088

Pw146088 View Pathway
drug action

Zinc oxide Drug Metabolism Action Pathway

Homo sapiens

PW132211

Pw132211 View Pathway
metabolic

Zinc phenolsulfonate Drug Metabolism

Homo sapiens
Zinc phenolsulfonate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zinc phenolsulfonate passes through the liver and is then excreted from the body mainly through the kidney.

PW146940

Pw146940 View Pathway
drug action

Zinc phenolsulfonate Drug Metabolism Action Pathway

Homo sapiens

PW146089

Pw146089 View Pathway
drug action

Zinc sulfate Drug Metabolism Action Pathway

Homo sapiens

PW146848

Pw146848 View Pathway
drug action

Zinc sulfate, unspecified form Drug Metabolism Action Pathway

Homo sapiens

PW128071

Pw128071 View Pathway
drug action

Ziprasidone Dopamine Antagonist Action Pathway

Homo sapiens
Ziprasidone is an atypical antipsychotic used to treat schizophrenia, bipolar mania, and acute agitation in schizophrenic patients. It also indicated improvement on the manic syndrome subscale that measures symptoms of mania such as mood, insomnia, excessive energy and activity, and overall behavior and ideation. Ziprasidone is also used as off-labeled for monotherapy in acute hypomania, monotherapy as maintenance treatment for adult patients with bipolar I disorder, hyperactivity treatment, and for the treatment of delirium in the ICU. Ziprasidone presents in both oral capsule and intramuscular injection formulations. Ziprasidone is an atypical antipsychotic that has a binding affinity for dopaminergic (DA), serotonergic (5HT), adrenergic (a1), and histaminergic (HA) receptors. Regarding treatment for schizophrenia, antagonism of the dopamine (D2) receptor in the mesolimbic pathway has proven efficacious in diminishing positive symptoms, whereas the antagonism of the 5HT2A receptor in the mesocortical pathway has demonstrated reduction of negative symptoms of psychosis. Its efficacy and mechanism of action for treating bipolar disorder are unknown. The antagonization of both histaminergic and adrenergic (a1) receptors can induce somnolence and orthostatic hypotension.